The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc Rights Issue Oversubscribed
In a pressrelease distributed April 12, 2018 Intervacc presented information about the outcome of the preferential share issue of Intervacc AB (publ) (“Intervacc” or “Company”) that was announced on February 18, 2018. The rights issue was...Intervacc has presented results from clinical trials at a scientific meeting on strangles
“Getting to grips with strangles” is a regularly recurring international scientific meeting on research on strangles a highly contagious horse disease. At the meeting held in Montanan, USA, in September 2017, Intervacc’s CEO, Jan-Ingmar Flock,...Intervacc has presented results from clinical trials at WEAS 2017
The WEAS (World Equine Airway Symposium) is a regularly recurring international scientific meeting on diseases of the horse’s airways. At WEAS 2017 in Copenhagen in July 2017, Intervacc CEO Jan-Ingmar Flock presented data from the clinical trials conducted with...Intervacc now on Introduce.se
Starting today March 1st, 2017 Intervacc becomes overviewed by Introduce.se Intervacc is now presented on introduce.se, a Swedish language website designed to provide overviews of publicly traded companies and to provide independent investor information. The...Nyhetstjänster
